NCT05585151 is a Phase 4 clinical trial of Evolocumab 140 MG/ML in Cerebral Atherosclerosis, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT05585151?

Interventions in NCT05585151: Evolocumab 140 MG/ML, Intensive statin treatment.

What condition does NCT05585151 study?

NCT05585151 studies Cerebral Atherosclerosis.

Is NCT05585151 still recruiting?

NCT05585151 is currently status unknown. Last updated 11 December 2023.

Last reviewed 2023-12-11 · How we verify

NCT05585151

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study

Status unknown Phase 4 Last updated 11 December 2023

What this trial tests

Phase 4 trial testing Evolocumab 140 MG/ML in Cerebral Atherosclerosis in 200 participants. Status unknown.

Timeline

9 November 2022

Primary endpoint
1 April 2024

1 October 2024

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	9 November 2022
Primary completion	1 April 2024
Estimated completion	1 October 2024
Sites	1 location across China

Drugs / interventions tested

Evolocumab 140 MG/ML — full drug profile →
Intensive statin treatment — full drug profile →

Conditions studied

Cerebral Atherosclerosis — all drugs for Cerebral Atherosclerosis →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

18 and older, any sex, with Cerebral Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study intends to explore the therapeutic effect of PCSK9i Evolocumab on atherosclerotic plaques in cerebral arteries (including carotid and vertebral arteries) compared with intensive statin treatment, and monitor the pathological properties of carotid/vertebral artery plaques with OCT technology. At the same time, three-dimensional ultrasound and high-resolution magnetic resonance are used to explore the new mechanism of pathological changes of cerebral atherosclerotic plaques in a multidimensional manner.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Evolocumab 140 MG/ML

Trials testing the same drug.

NCT05661552 — Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI · Phase 4 · completed
NCT04951856 — Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI · Phase 4 · active not recruiting
NCT03932721 — EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial · Phase 4 · completed

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05585151 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 11 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05585151.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing